Teriflunomide: Agent for multiple sclerosis dihydroorotate dehydrogenase inhibitor

Drugs of the Future

Volumn 30, Issue 11, 2005, Pages 1102-1106

  Boyd, B ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE INHIBITOR; HMR 1726; LEFLUNOMIDE; MALONONITRILAMIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; RS 61980; SU 0020; TERIFLUNOMIDE;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; PYRIMIDINE SYNTHESIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS;

EID: 33645100372     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.11.948823     Document Type: Review

References (20)

1. Bartlett, R.R., Kämmerer, F.-J. (Sanofi-Aventis). Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs. EP 0527736, JP 1993506425, JP 1999322700, JP 1999343285, US 5494911, US 5532259, WO 1991017748.
2. Hirth, K.P., Schwartz, D.P., Mann, E., Shawver, L.K., Kéri, G., Székely, I., Bajor, T., Haimichael, J., Orfi, L., Levitzki, A., Gazit, A., Ullrich, A., Lammers, R., Kabbinavar, F.F., Slamon, D.J., Tang, C.P. (Sugen, Inc.; Yissum Research Development Co.; The Hebrew University; Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV). Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor. EP 1000617, US 5700823, WO 1995019169.
3. Mahajan, S., Ghosh, S., Sudbeck, E.A., Zheng, Y., Downs, S., Hupke, M., Uckun, F.M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy- β-methyl-N-(2, 5-dibromophenyl)-propenamide]. J Biol Chem 1999, 274: 9587-99.
4. Hachtel, J., Neises, B., Schwab, W., Utz, R., Zahn, M. (Aventis Pharma Deutschland GmbH). Method for producing 2-cyan-3-hydroxy-N-(phenyl)but-2-ene amides. DE 10311763, US 2004186173, US 6894184, WO 2004083165.
5. Greene, S., Watanabe, K., Braatz-Trulson, J., Lou, L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995, 50: 861-7.
6. Davis, J.P., Cain, G.A., Pitts, W.J., Magolda, R.L., Copeland, R.A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. FASEB J 1996, 10(6): Abst C23.
7. Davis, J.P., Cain, G.A., Pitts, W.J., Magolda, R.L., Copeland, R.A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996, 35: 1270-3.
8. Williamson, R.A., Yea, C.M., Robson, P.A. et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A 77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995, 270: 22467-72.
9. Xu, X., Williams, J.W., Gong, H., Finnegan, A., Chong, A.S.-F. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Biochem Pharmacol 1996, 52: 527-34.
10. Elder, R.T., Xu, X., Williams, J.W., Gong, H., Finnegan, A., Chong, A.S.-F. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997, 159: 22-7.
11. Bruneau, J.-M., Yea, C.M., Spinella-Jaegle, S. et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998, 336: 299-303.
12. Schorlemmer, H.U., Milbert, U., Haun, G., Wunschel, M., Zeitter, D., Schleyerbach, R. De novo pyrimidine biosynthesis in Jurkat T-cells is inhibited by leflunomide's primary metabolite A77-1726 at the level of dihydroorotate-dehydrogenase (DHODH). Int J Immunother 1998, 14: 193-204.
13. Czech, J., Kurrle, R., Schorlemmer, H.U. Inhibition of smooth muscle cell proliferation by A77-1726 and its derivatives can be antagonized by uridine. Int J Immunother 1998, 14: 185-91.
14. Schorlemmer, H.U., Kurrle, R., Schleyerbach, R. Leflunomide's active metabolite A77-1726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytes. Int J Immunother 1998, 14: 213-22.
15. Zeyda, M., Poglitsch, M., Geyeregger, R. et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005, 52: 2730-9.
16. Milenkovic, P., Ivanovic, Z., Dimitrijevic, M., Bartlett, R.R. The effect of a novel compound HWA 486 metabolite A771726 on proliferation of spleen colony-forming cells. Exp Hematol 1995, 23: Abst 121.
17. Styren, S.D., Barbier, A.J., Selk, D.E., Wettstein, J.G. Beneficial effects of teriflunomide in experimental allergic encephalomyelitis. 34th Annu Meet Soc Neurosci (Oct 23-27, San Diego) 2004, Abst 344.5.
18. Li, D.K.B., O'Connor, P., Freedman, M. et al. Oral teriflunomide is safe and effective in multiple sclerosis with relapses: Results of a randomized, placebo-controlled phase II study. Multiple Scler 2004, 10(Suppl. 2): Abst P685.
19. Oger, J., Aziz, T., Gibbs, E., Dorovini-Zis, K. Multiple sclerosis patients treated with teriflunomide have improved in vitro IgG secretion and endothelial cell adhesion (a pilot study). Multiple Scler 2004, 10(Suppl. 2): Abst P684.
20. Phase III study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (NCT00134563). ClinicalTrials.gov Web Site 2005, October 25.